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Clinical PerspectiveWhat Is New?This nationwide retrospective cohort (n=2778 individuals with systemic sclerosis) study spanning 1995--2015 confirms and quantifies a wide spectrum of cardiovascular complications for systemic sclerosis patients compared with a general‐population control group.We observed that both well‐established manifestations (eg, pulmonary hypertension) and less evaluated cardiovascular complications (eg, myocardial infarction, peripheral vascular disease, aortic and mitral regurgitation) were more prevalent at the time of diagnosis and during follow‐up among patients with systemic sclerosis versus controls.What Are the Clinical Implications?The increased prevalence, incidence, and relative risk of cardiovascular manifestations in systemic sclerosis underscore a significant adverse impact of systemic sclerosis across the vascular bed and specific cardiac structures, warranting increased focus on less recognized complications.

 {#jah34388-sec-0008}

Systemic sclerosis (SSc; also called scleroderma) is a connective tissue disease with substantially increased cardiopulmonary morbidity and mortality.[1](#jah34388-bib-0001){ref-type="ref"} Microvascular impairment is a pathognomonic feature in SSc with manifestations such as Raynaud phenomenon, pulmonary arterial hypertension, and renal crisis being well characterized. Several pathways in SSc vasculopathy (eg, endothelial dysfunction, inflammation, impaired coagulation or fibrinolysis, and oxidative stress) may lead to atherosclerotic manifestations.[2](#jah34388-bib-0002){ref-type="ref"} Moreover, SSc‐related vasculopathy combined with immune dysregulation and progressive fibrosis (hallmark features of SSc) are implicated in the pathogenesis of large vessel disease and specific cardiac dysfunction, but the clinical impact remains uncertain.[3](#jah34388-bib-0003){ref-type="ref"}, [4](#jah34388-bib-0004){ref-type="ref"}, [5](#jah34388-bib-0005){ref-type="ref"}

A recent Danish study found SSc to be a significant risk factor for all‐cause cardiovascular disease (defined as a composite end point including death due to cardiovascular disease).[6](#jah34388-bib-0006){ref-type="ref"} However, few studies have examined the incidence of individual macrovascular manifestations such as myocardial infarction, stroke, peripheral artery disease, and venous thromboembolism[7](#jah34388-bib-0007){ref-type="ref"}, [8](#jah34388-bib-0008){ref-type="ref"}, [9](#jah34388-bib-0009){ref-type="ref"} and data on the prevalence of valvular heart disease and arrhythmias in SSc are scarse.[10](#jah34388-bib-0010){ref-type="ref"}, [11](#jah34388-bib-0011){ref-type="ref"}, [12](#jah34388-bib-0012){ref-type="ref"}, [13](#jah34388-bib-0013){ref-type="ref"} We aimed to investigate the burden of cardiovascular disease in a nationwide sample of patients with incident SSc compared with matched controls. Using the Danish healthcare registers, we specifically estimated the prevalence and incidence of ischemic manifestations (acute myocardial infarction, stroke, peripheral vascular disease), arrhythmias (atrial fibrillation), conduction blocks (atrioventricular and left bundle‐branch block) and hitherto unknown risk of device implantation (pacemaker or implantable cardioverter‐defibrillator), cardiac valve disease (aortic and mitral stenosis and regurgitation), aortic disease (aortic aneurysm and dissection), and established manifestations including pulmonary hypertension, heart failure, pericarditis, and venous thromboembolism in SSc. We hypothesized that patients with SSc would be at increased risk of cardiac and vascular manifestations across the whole spectrum of cardiovascular diseases.

Methods {#jah34388-sec-0009}
=======

Data obtained through the nationwide registers in Denmark can be made available only through research on Danish servers hosted in highly protected research environments where researchers can be granted access and permission with encrypted person identification. Access to raw data can be gained only through collaboration with the authors or other Danish institutions that already have been granted access. Please contact the first author with any questions regarding data access. Additional methods can be found in Data [S1](#jah34388-sup-0001){ref-type="supplementary-material"}.

Study Design {#jah34388-sec-0010}
------------

The study is a nationwide cohort study that included all patients with a first‐time registration of SSc versus age‐ and sex‐matched controls (1:5) from the Danish healthcare registries between January 1, 1995, and December 31, 2015. The study was conceived in agreement with the recommendations for cohort studies by the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) initiative.[14](#jah34388-bib-0014){ref-type="ref"}

Data Sources {#jah34388-sec-0011}
------------

For this study we cross‐linked the Central Population Registry (using individual‐level data) with the National Patient Registry and the National Prescription Registry. The Central Population Registry contains the unique personal identification numbers of all Danish residents along with information on their birth date, sex, and vital status. The National Patient Registry contains information on all in‐ and out‐hospital diagnoses, registered according to the *International Classification of Diseases* (*ICD*) system, using the *Eighth Revision* (*ICD‐8*) from 1978 to 1993 and the *Tenth Revision* (*ICD‐10*) since 1994. The accuracy and completeness of diagnostic coding in the National Patient Registry has been evaluated as consistently high for a variety of chronic comorbidities and cardiovascular diagnoses,[15](#jah34388-bib-0015){ref-type="ref"}, [16](#jah34388-bib-0016){ref-type="ref"}, [17](#jah34388-bib-0017){ref-type="ref"}, [18](#jah34388-bib-0018){ref-type="ref"} and we have previously found a positive predictive value of 94% for the SSc diagnosis in this registry.[19](#jah34388-bib-0019){ref-type="ref"} The National Prescription Registry holds information on all prescription claims since 1995 with all drugs classified according to the Anatomical Therapeutic Chemical (ATC) classification system. Because of reimbursement‐driven policy, this registry is considered high quality.[20](#jah34388-bib-0020){ref-type="ref"}

Study Population {#jah34388-sec-0012}
----------------

In the National Patient Registry, we identified all first‐time diagnoses of SSc (*ICD‐10* codes M34, except for M34.2) that followed outpatient or inpatient visits between 1995 and 2015. We excluded patients with a prior diagnosis of SSc, defined as an *ICD‐10* code of M34 in 1994 or an *ICD‐8* code of 734 anytime between 1978 and 1993. The controls consisted of 5 randomly selected age‐ and sex‐matched individuals from the Central Population Registry. An index date was assigned to each control that corresponded to the date of first registration of SSc for his or her respective case, in accordance with the principle of incidence density sampling.[21](#jah34388-bib-0021){ref-type="ref"}

Outcome Variables and Follow‐Up {#jah34388-sec-0013}
-------------------------------

The primary outcome variables were defined by *ICD‐8* and *ICD‐10* codes, together with procedural codes (obtained via the National Patient Registry) and medication use (obtained via the ATC Classification System coding in the National Prescription Registry). Table [S1](#jah34388-sup-0001){ref-type="supplementary-material"} shows the different variables, different registries, and corresponding diagnosis or procedure/surgical codes for each outcome.

Comorbidity and Medications {#jah34388-sec-0014}
---------------------------

Baseline comorbidity comprised prevalent conditions at any time before study inclusion. Comorbidity included hypertension, atrial fibrillation, heart failure of any cause, myocardial infarction, ischemic stroke, aortic aneurism and dissection, aortic stenosis and regurgitation, mitral stenosis and regurgitation, conduction block (left bundle‐branch block and atrioventricular block), implantation of pacemaker or implantable cardioverter‐defibrillator, pericarditis, peripheral vascular disease, pulmonary hypertension, venous thromboembolism, treated dyslipidemia, and diabetes mellitus. Baseline treatment was defined by at least 1 prescription dispensed for each respective drug up to 180 days before the study inclusion date. The following drugs were included: aspirin, NSAIDs, statins, oral anticoagulants, antiplatelet therapy, and glucocorticoids.

Statistical Analysis {#jah34388-sec-0015}
--------------------

Continuous variables are presented as mean±SD, and categorical variables are presented as absolute numbers and percentages. Tests for differences between groups were performed by the Pearson χ^2^ or Fisher exact test (categorical data) or by the Student *t* test (continuous data), as appropriate. Time at risk was measured from the index date (date of SSc diagnosis), and individuals were censored at the date of first‐time registration of the specific end point, migration, or death. Conditional logistic regression models and Cox proportional hazards regression models were used respectively to calculate the odds ratios (ORs) for prevalent cardiovascular diseases and hazard ratios (HRs) for incident diseases associated with SSc. Separate models were run for each end point. The main models were adjusted for age and sex. In addition, a multivariable Cox regression model (including all comorbidities and treatment in Table [1](#jah34388-tbl-0001){ref-type="table"}) was applied to investigate the association of SSc and outcomes after adjustment for various comorbidities and risk factors. Two‐sided *P*\<0.05 was considered statistically significant for all analyses. All analyses were performed in SAS v9.4 (SAS Institute).

###### 

Baseline Characteristics of SSc Patients and Controls

  Variable                                                          SSc Cases (n=2778)   Controls (n=13 890)   *P* Value
  ----------------------------------------------------------------- -------------------- --------------------- -----------
  Female sex                                                        2114 (76)            10 570 (76)           
  Age, y, mean±SD                                                   55±15                55±15                 
  Hypertension                                                      867 (31.2)           2915 (21.0)           \<0.0001
  Atrial fibrillation and atrial flutter                            77 (2.8)             189 (1.1)             \<0.0001
  Heart failure                                                     84 (3)               166 (1)               \<0.0001
  Myocardial infarction                                             86 (3.1)             260 (1.9)             \<0.0001
  Ischemic stroke                                                   69 (1.3)             224 (2.5)             \<0.0001
  Aortic aneurism                                                   9 (0.3)              25 (0.2)              0.1247
  Aortic dissection                                                 ≤3                   ≤3                    0.4385
  Aortic stenosis                                                   15 (0.5)             35 (0.3)              0.0113
  Aortic regurgitation                                              19 (0.7)             30 (0.2)              \<0.0001
  Mitral stenosis                                                   ≤3                   ≤3                    0.1615
  Mitral regurgitation                                              13 (0.5)             32 (0.2)              0.0276
  Conduction block (left bundle‐branch or atrioventricular block)   15 (0.5)             28 (0.2)              0.0013
  Pacemaker/implantable cardioverter‐defibrillator                  18 (0.7)             54 (0.4)              0.0572
  Pericarditis                                                      28 (1.0)             29 (0.2)              \<0.0001
  Peripheral vascular disease                                       121 (4.4)            133 (1.0)             \<0.0001
  Pulmonary hypertension                                            22 (0.8)             14 (0.1)              \<0.0001
  Venous thromboembolism                                            93 (3.4)             156 (1.1)             \<0.0001
  Diabetes mellitus                                                 139 (5.0)            585 (4.2)             0.0616
  Aspirin                                                           344 (12.4)           1055 (7.6)            \<0.0001
  NSAIDs                                                            752 (27.1)           1733 (12.5)           \<0.0001
  Glucocorticoids                                                   379 (13.6)           352 (2.5)             \<0.0001
  Treated dyslipidemia                                              273 (9.8)            1177 (8.5)            0.0208
  Oral anticoagulant                                                109 (3.9)            176 (1.3)             \<0.0001
  Antiplatelet therapy                                              375 (13.5)           1153 (8.3)            \<0.0001

Data are shown as n (%) except as noted. SSc indicates systemic sclerosis.

Ethics {#jah34388-sec-0016}
------

All data were anonymized to the investigators. The study was approved by the Danish Data Protection Agency (ref. 2007‐58‐0015, int. ref. GEH‐2014‐018, I‐suite 02736). Because the study is retrospective and registry‐based using deidentified data, Danish law does not require ethics approval. The Danish procedures for safeguarding patient anonymity prohibit the reporting of outcomes with ≤3 events. The first author had full access to the data and takes responsibility for its integrity and for the data analysis.

Results {#jah34388-sec-0017}
=======

Study Population {#jah34388-sec-0018}
----------------

The demographic characteristics and baseline comorbidities for patients with SSc and matched controls are shown in Table [1](#jah34388-tbl-0001){ref-type="table"}. The study population comprised 2778 patients (76% female) with a diagnosis of SSc and 13 890 controls with an overall follow‐up time of 8.9 years. A total of 722 (26%) and 1.938 (14%) patients died in the SSc and matched cohorts, respectively, with an age‐ and sex‐adjusted HR for all‐cause mortality of 2.68 (95% CI, 2.43--2.94).

The presence of other autoimmune tissue disorders was low but higher among patients with SSc than controls (114 \[4.1%\] versus 97 \[0.7%\] for rheumatoid arthritis, 41 \[1.5%\] versus 8 \[0.06%\] for systemic lupus erythematosus, and 48 \[1.7%\] versus 4 \[0.03%\] for mixed connective tissue disease; all *P* \<0.0001). Cardiovascular risk factors such as hypertension (OR: 1.82; 95% CI, 1.66--2.01) and treated dyslipidemia (OR: 1.21; 95% CI, 1.04--1.40) were more frequent in the SSc cohort compared with control participants. The prevalence of most cardiovascular disorders was found to be higher in the SSc cohort than in the matched population. Very few SSc patients had either aortic disease (≤9) or mitral stenosis (≤3) at baseline.

Incidence rates for new‐onset cardiovascular manifestations are presented in Table [2](#jah34388-tbl-0002){ref-type="table"}. Table [2](#jah34388-tbl-0002){ref-type="table"} also shows the total number of events in each cohort in patients with SSc and controls for all outcomes. SSc patients had higher risks ([Figure](#jah34388-fig-0001){ref-type="fig"}) of developing myocardial infarction (HR: 2.08; 95% CI, 1.65--2.64), ischemic stroke (HR: 1.28; 95% CI, 1.04--1.58), peripheral vascular disease (HR: 5.73; 95% CI, 4.63--7.09), atrial fibrillation (HR: 1.75; 95% CI, 1.51--2.04), heart conduction block (atrioventricular and left bundle‐branch; HR: 1.73; 95% CI, 1.14--2.62), pulmonary hypertension (HR: 21.18; 95% CI, 14.73--30.45), heart failure (HR: 2.86; 95% CI, 2.43--3.37), pericarditis (HR: 8.78; 95% CI, 4.84--15.93), mitral regurgitation (HR: 4.60; 95% CI, 3.12--6.79), aortic regurgitation (HR: 3.78; 95% CI, 2.55--5.58) and stenosis (HR: 2.99; 95% CI, 2.025--3.97), and venous thromboembolism (HR: 2.10; 95% CI, 1.65--2.67). The proportions of patients with incident myocardial infarction who were revascularized within 30 days (either by coronary artery bypass grafting surgery or percutaneous coronary intervention) were similar for SSc cases and controls (31% versus 35%; *P*=0.44).

###### 

Incidence of Various Cardiovascular Comorbidities and Conditions During Follow‐Up

  Variable                                                           SSc Cases (n=2778)   Controls (n=13 520)           
  ------------------------------------------------------------------ -------------------- ---------------------- ------ --------------------
  Hypertension                                                       1320                 15.21 (14.42--16.06)   5081   6.96 (6.77--7.16)
  Atrial fibrillation                                                235                  0.92 (0.81--1.04)      713    0.54 (0.50--0.58)
  Heart failure                                                      229                  0.92 (0.81--1.05)      451    0.34 (0.31--0.37)
  Myocardial infarction                                              100                  0.39 (0.32--0.48)      252    0.19 (0.17--0.22)
  Ischemic stroke                                                    112                  0.43 (0.36--0.52)      439    0.33 (0.31--0.37)
  Aortic aneurism                                                    21                   0.08 (0.05--0.12)      74     0.05 (0.04--0.07)
  Aortic dissection                                                  ≤3                   NA                     12     0.01 (0.005--0.02)
  Aortic stenosis                                                    77                   0.29 (0.23--0.36)      133    0.10 (0.08--0.12)
  Aortic regurgitation                                               44                   0.16 (0.12--0.22)      58     0.04 (0.03--0.05)
  Mitral stenosis                                                    6                    0.02 (0.01--0.05)      ≤3     NA
  Mitral regurgitation                                               49                   0.18 (0.14--0.24)      53     0.04 (0.03--0.05)
  Conduction block (left bundle‐ branch or atrioventricular block)   30                   0.11 (0.08--0.16)      91     0.07 (0.05--0.08)
  Pacemaker or implantable cardioverter‐defibrillator                48                   0.18 (0.13--0.23)      137    0.10 (0.08--0.12)
  Pericarditis                                                       30                   0.11 (0.08--0.16)      18     0.01 (0.01--0.02)
  Peripheral vascular disease                                        184                  0.75 (0.65--0.87)      182    0.14 (0.12--0.16)
  Pulmonary hypertension                                             153                  0.58 (0.49--0.68)      36     0.02 (0.02--0.04)
  Venous thromboembolism                                             95                   0.37 (0.30--0.46)      232    0.17 (0.15--0.20)

NA indicates not assessed; SSc, systemic sclerosis.

![Forest plot. Odds ratio (prevalent disease) or hazard ratio (incident disease) for various cardiovascular conditions associated with systemic sclerosis, adjusted for age and sex. Relative risks are expressed as odds ratios for prevalent diseases and hazard ratios for incident diseases. \*Defined as atherosclerosis in peripheral artery or aorta.](JAH3-8-e013405-g001){#jah34388-fig-0001}

Further adjustment for medications (aspirin, NSAIDs, glucocorticoids, statins, oral anticoagulants, and platelet inhibitors) and comorbidities yielded results similar to the main analyses (Table [S2](#jah34388-sup-0001){ref-type="supplementary-material"}), except for ischemic stroke (HR: 1.13; 95% CI, 0.90--1.42).

Validation {#jah34388-sec-0019}
----------

To increase the likelihood of causality underlying our observations, we used the 2 known genetic variants associated with SSc from prior genome‐wide association studies, *rs3894194* and *rs4134466*, as instrument variables to look for associations with various cardiovascular disorders in the UK Biobank.[22](#jah34388-bib-0022){ref-type="ref"}, [23](#jah34388-bib-0023){ref-type="ref"} Multiple disorders, including myocardial infarction, heart failure, aneurisms, arrhythmias, and peripheral vascular disease were associated with the single‐nucleotide polymorphisms at *P*\<0.05 (Table [S3)](#jah34388-sup-0001){ref-type="supplementary-material"}. In addition, evidence suggested a causal association with nonrheumatic mitral valve disease (*P*=0.058).

Discussion {#jah34388-sec-0020}
==========

In this nationwide cohort study comprising all Danish SSc patients from 1995 to 2015 and matched controls, we confirm well‐known associations between SSc and pulmonary hypertension, pericarditis, and atrial fibrillation. In addition, we show that less evaluated cardiovascular complications (ischemic manifestations, valvular disease, venous thromboembolism) are both more prevalent at the time of SSc diagnosis and occur at higher incidence rates after diagnosis in SSc patients compared with matched controls. In contrast to the established cardiovascular manifestations of SSc (eg, pericarditis), the increased risks associated with several of the less well‐recognized diseases were moderate. However, given the overall higher prevalence and incidence rates of the many cardiovascular manifestations, increased attention to the risk of cardiovascular diseases in SSc patients is warranted.

Atherosclerotic Cardiovascular Disease {#jah34388-sec-0021}
--------------------------------------

Systemic inflammatory autoimmune diseases are associated with premature atherosclerosis. Although the degree of overt systemic inflammation and renal involvement may be less profound in SSc than in, for example, systemic lupus (which is well known to be associated with atherosclerosis, especially in the presence of nephropathy),[24](#jah34388-bib-0024){ref-type="ref"}, [25](#jah34388-bib-0025){ref-type="ref"} we hypothesize that part of the observed association may be due to inflammation in SSc.[26](#jah34388-bib-0026){ref-type="ref"}, [27](#jah34388-bib-0027){ref-type="ref"} A few studies of limited size have suggested that patients with SSc have similar or lower prevalence of traditional cardiovascular risk factors such as hypertension, dyslipidemia, and diabetes mellitus compared with controls.[7](#jah34388-bib-0007){ref-type="ref"}, [28](#jah34388-bib-0028){ref-type="ref"}, [29](#jah34388-bib-0029){ref-type="ref"} In contrast, our study observed higher prevalence of hypertension, treated dyslipidemia, and diabetes mellitus in patients with SSc than controls. Similar to our findings, registries have pointed toward increased prevalence of coronary heart disease in SSc patients compared with controls,[30](#jah34388-bib-0030){ref-type="ref"} with recent studies showing a 2.0‐ to 3.5‐fold increased relative risk of myocardial infarction.[7](#jah34388-bib-0007){ref-type="ref"}, [28](#jah34388-bib-0028){ref-type="ref"}, [31](#jah34388-bib-0031){ref-type="ref"}

Peripheral vascular disease in SSc has recently come into focus with the use of angiography and subclinical markers such as pulse wave velocity, ankle brachial index, and systolic/diastolic interarm difference.[32](#jah34388-bib-0032){ref-type="ref"}, [33](#jah34388-bib-0033){ref-type="ref"}, [34](#jah34388-bib-0034){ref-type="ref"} Few studies have been conducted, but a recent case--control study comprising 858 individuals with SSc found incidence rates (7.6/1000 person‐years) and HRs (4.57; 95% CI, 2.99--7.01) similar to ours.[7](#jah34388-bib-0007){ref-type="ref"} Aortic disease (aneurysm or dissection) involvement has been reported in only a few case reports,[35](#jah34388-bib-0035){ref-type="ref"} and our study confirms it being uncommon in SSc. Cerebral vascular involvement in patients with SSc has been studied previously by assessing carotid intima media thickness, and findings have been inconclusive findings,[36](#jah34388-bib-0036){ref-type="ref"}, [37](#jah34388-bib-0037){ref-type="ref"} although higher prevalence of intracerebral calcifications[38](#jah34388-bib-0038){ref-type="ref"} and white matter hyperintensities[39](#jah34388-bib-0039){ref-type="ref"} has been suggested in patients with SSc compared with age‐ and sex‐matched controls. In contrast to a few prior smaller studies,[40](#jah34388-bib-0040){ref-type="ref"}, [41](#jah34388-bib-0041){ref-type="ref"} some recent studies have shown a slightly increased risk of ischemic stroke (HR: 1.44--2.56) in patients with SSc compared with controls.[7](#jah34388-bib-0007){ref-type="ref"}, [31](#jah34388-bib-0031){ref-type="ref"}, [42](#jah34388-bib-0042){ref-type="ref"} Our findings of an increased crude risk of ischemic stroke partially mirror findings of a disproportionately lower relative risk of ischemic cerebral disease compared with the risk of ischemic heart disease and peripheral vascular disease, albeit insignificant in the fully adjusted model.

Arrhythmias and Conduction Defects {#jah34388-sec-0022}
----------------------------------

Arrhythmias and cardiac conduction defects are common in SSc, presumably because of myocardial ischemic, fibrotic, and inflammatory lesions.[43](#jah34388-bib-0043){ref-type="ref"} In selected SSc cohorts, electrophysiological abnormalities have been reported in 25% to 85% of patients and transient atrial arrhythmias reported in 20% to 30%.[12](#jah34388-bib-0012){ref-type="ref"}, [44](#jah34388-bib-0044){ref-type="ref"} Our study confirms an increased prevalence (2.8%) at the time of diagnosis and almost 2‐fold increased relative risk of atrial fibrillation for SSc patients during follow‐up; a similar 2‐fold risk of implantation of pacemakers and cardioverter‐defibrillators was found in the SSc cohort.

Pulmonary Hypertension and Heart Failure {#jah34388-sec-0023}
----------------------------------------

Pulmonary hypertension and resulting right‐sided heart failure is a significant cause of morbidity and mortality in SSc.[45](#jah34388-bib-0045){ref-type="ref"} In contrast, echocardiographically diagnosed left ventricular systolic dysfunction is infrequently seen (≈5%),[46](#jah34388-bib-0046){ref-type="ref"} although diastolic dysfunction may contribute more to mortality than recognized previously.[47](#jah34388-bib-0047){ref-type="ref"} Of note, subclinical myocardial abnormalities are detected more often by tissue Doppler or magnetic resonance imaging than with conventional echocardiography, in line with the typically gradual and subtle disease progression over time.[48](#jah34388-bib-0048){ref-type="ref"} The prevalence of pulmonary hypertension is estimated to be ≈7%,[49](#jah34388-bib-0049){ref-type="ref"} and incidence estimates have been reported to be 1.37 to 1.85/100 person‐years, based on modalities such as echocardiography and right heart catheterization.[50](#jah34388-bib-0050){ref-type="ref"}, [51](#jah34388-bib-0051){ref-type="ref"} Our register‐based prevalence at time of diagnosis and incidence rate estimates of 0.58/100 person‐years (95% CI, 0.6--0.8) are lower than expected. Because the manifestation is insidious, our findings could be explained in part by the study design, the time span applied, and the modalities required (echocardiography, right heart catheterization), making it likely that SSc‐related pulmonary hypertension may be underdiagnosed and underreported in the National Patient Registry. However, the 21‐fold increased relative risk of pulmonary hypertension (HR: 21.18; 95% CI, 14.73--30.45) during follow‐up underscores the well‐known association between SSc and pulmonary hypertension.

Pericarditis {#jah34388-sec-0024}
------------

Pericardial involvement in SSc was first described in autopsy studies[52](#jah34388-bib-0052){ref-type="ref"} and may occur in 2 patterns.[53](#jah34388-bib-0053){ref-type="ref"} Consistent with prior autopsy studies, pericardial involvement has been characterized through modalities like echocardiography[10](#jah34388-bib-0010){ref-type="ref"}, [54](#jah34388-bib-0054){ref-type="ref"} and magnetic resonance imaging[55](#jah34388-bib-0055){ref-type="ref"} as being an indolent chronic process, often with smaller pericardial effusions that are not always clinically apparent. However, it can also present as an acute disorder with symptomatic pericarditis for which larger effusions are known to be associated with poorer prognosis.[53](#jah34388-bib-0053){ref-type="ref"}, [56](#jah34388-bib-0056){ref-type="ref"}, [57](#jah34388-bib-0057){ref-type="ref"} Literature on the prevalence and risk of symptomatic pericarditis is scarce. We found that overt pericarditis leading to clinical registration occurred in 1% of SSc patients at time of diagnosis, with a 6‐fold increased relative risk during follow‐up. Nevertheless, the absolute numbers are low, indicating that clinical symptomatic pericarditis remains a rare complication.

Cardiac Valve Disease {#jah34388-sec-0025}
---------------------

Cardiac valve disease has not gained much attention even though early autopsy studies described minor valvular lesions in patients with SSc.[52](#jah34388-bib-0052){ref-type="ref"} A few echocardiographic studies have reported an association between SSc and, particularly, valvular regurgitation,[10](#jah34388-bib-0010){ref-type="ref"}, [11](#jah34388-bib-0011){ref-type="ref"}, [58](#jah34388-bib-0058){ref-type="ref"} but the risk of incident valve disease has not been studied previously. In our study, we found a 3‐fold increased relative risk of aortic stenosis, a 4‐fold increased relative risk of aortic regurgitation, and an almost 5‐fold increased relative risk of mitral regurgitation. The relative risk of mitral stenosis was similarly found to be increased 10‐fold but limited by a small number of cases and a wide CI. In accordance with a recent Swedish study,[59](#jah34388-bib-0059){ref-type="ref"} our findings illustrate that cardiac valve disease can develop during the natural history of disease and thus be regarded as a specific SSc‐related complication.

Venous Thromboembolism {#jah34388-sec-0026}
----------------------

Autoimmune disorders are recognized as risk factors for venous thromboembolism, presumably because of chronic inflammation and hypercoagulability.[60](#jah34388-bib-0060){ref-type="ref"} Prior studies imply an increased risk of venous thrombosis; for instance, a recent meta‐analysis based on 5 studies, although hampered by high statistical heterogeneity, reported a pooled risk ratio of 2.51 (95% CI, 1.79--3.54).[9](#jah34388-bib-0009){ref-type="ref"} Our observations of doubled risk are in line with these earlier reports, adding weight to the association between SSc and venous thromboembolism. The mechanistic link, however, cannot be determined from our study. It is possible that although the prevalence of rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disorders was small (\<5%) in our study cohort, some of the observed association between SSc and venous thromboembolism (and potentially other cardiovascular disorders) was driven by the presence of these and other autoimmune comorbidities.

Study Strengths and Weaknesses {#jah34388-sec-0027}
------------------------------

Danish registries are considered accurate and complete and can contribute to the study of rare diseases.[61](#jah34388-bib-0061){ref-type="ref"} Because almost all patients in Denmark with SSc are followed in specialized departments of rheumatology or dermatology, selection and recall bias as a source of error is low given the nationwide administrative setup. However, a detection bias of cardiovascular diseases may have occurred in the SSc cohort because of the regular specialized care and surveillance (eg, valvular diseases may have been detected because of more frequent echocardiography). Bias could also be introduced if SSc patients had diagnoses coded more often than controls because of a more thorough coding practice by their treating physicians. However, because of the Danish reimbursement policy, physicians should code only clinically significant conditions of importance to the specific contact (eg, valve disorders should be coded only if they require follow‐up), making such bias less likely. Our observations were also strengthened by genetic evidence suggesting a causal relationship between SSc and many of the cardiovascular manifestations, underscoring that surveillance and coding practices might not be solely responsible for the observed associations. The main strength of the study includes the high number of cases and the long duration of follow‐up. Considering the high validity in the National Patient Registry of the exposure and outcome variables used in this study,[15](#jah34388-bib-0015){ref-type="ref"}, [16](#jah34388-bib-0016){ref-type="ref"}, [17](#jah34388-bib-0017){ref-type="ref"}, [19](#jah34388-bib-0019){ref-type="ref"} the potential for inaccurate diagnosis and consequently misleading calculations should be low; however, it should be acknowledged that a few diagnoses (eg, pulmonary hypertension) have never been validated. Furthermore, the diagnoses could not be used to subclassify the disease severity (eg, severity of an aortic stenosis). In the multivariable analysis, several end points had a relatively low number of incident cases, and the rule of thumb that the number of events should be at least 10 times the number of covariates was not met for all end points. Therefore, caution is advised when interpreting the results from the multivariable analysis. Of note, our study spans a time period in which the classification criteria of SSc have evolved,[62](#jah34388-bib-0062){ref-type="ref"}, [63](#jah34388-bib-0063){ref-type="ref"}, [64](#jah34388-bib-0064){ref-type="ref"} and the increasing use of serological markers and capillaroscopy, for example, have yielded increases in the number of patients fulfilling disease criteria.[65](#jah34388-bib-0065){ref-type="ref"}, [66](#jah34388-bib-0066){ref-type="ref"}, [67](#jah34388-bib-0067){ref-type="ref"} It is likely that our cohort contained a larger proportion of early and mild disease compared with earlier cohorts, although we did not have information allowing us to differentiate distinct phenotypes of SSc with regard to extent of skin involvement or serological features known to be associated with mortality in SSc.[68](#jah34388-bib-0068){ref-type="ref"} Moreover, residual confounding cannot be refuted because valid information on lifestyle parameters (eg, tobacco, alcohol, body mass index, physical activity level) is not available in the registries used for this study. Our cohort was based on a homogeneous ethnic northern European population, making extrapolation to other ethnicities difficult.

Conclusions {#jah34388-sec-0028}
===========

The magnitude of cardiovascular manifestations estimated in our study suggests a significant disease‐related adverse impact across the vascular bed and specific cardiac structures, warranting an increased focus on less recognized complications. The limited understanding of the pathology and dynamics behind our multifaceted findings reflects an unmet need for characterization of key determinants of risk and causal factors of cardiovascular complications in SSc. Our findings require more research; however, our study supports a multidisciplinary approach for the assessment of cardiovascular disease and its treatment in patients with SSc.
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